These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

394 related items for PubMed ID: 26906901

  • 1. Platinum (IV)-fatty acid conjugates overcome inherently and acquired Cisplatin resistant cancer cell lines: an in-vitro study.
    Ratzon E, Najajreh Y, Salem R, Khamaisie H, Ruthardt M, Mahajna J.
    BMC Cancer; 2016 Feb 23; 16():140. PubMed ID: 26906901
    [Abstract] [Full Text] [Related]

  • 2. Dual-targeting antitumor conjugates derived from platinum(IV) prodrugs and microtubule inhibitor CA-4 significantly exhibited potent ability to overcome cisplatin resistance.
    Huang X, Wang M, Wang C, Hu W, You Q, Yang Y, Yu C, Liao Z, Gou S, Wang H.
    Bioorg Chem; 2019 Nov 23; 92():103236. PubMed ID: 31494328
    [Abstract] [Full Text] [Related]

  • 3. High effectiveness of platinum(IV) complex with adamantylamine in overcoming resistance to cisplatin and suppressing proliferation of ovarian cancer cells in vitro.
    Kozubík A, Horváth V, Svihálková-Sindlerová L, Soucek K, Hofmanová J, Sova P, Kroutil A, Zák F, Mistr A, Turánek J.
    Biochem Pharmacol; 2005 Feb 01; 69(3):373-83. PubMed ID: 15652229
    [Abstract] [Full Text] [Related]

  • 4. Cellular accumulation and cytotoxicity of macromolecular platinum complexes in cisplatin-resistant tumor cells.
    Garmann D, Warnecke A, Kalayda GV, Kratz F, Jaehde U.
    J Control Release; 2008 Oct 21; 131(2):100-6. PubMed ID: 18691617
    [Abstract] [Full Text] [Related]

  • 5. Copper transporters and the cellular pharmacology of the platinum-containing cancer drugs.
    Howell SB, Safaei R, Larson CA, Sailor MJ.
    Mol Pharmacol; 2010 Jun 21; 77(6):887-94. PubMed ID: 20159940
    [Abstract] [Full Text] [Related]

  • 6. Toward overcoming cisplatin resistance via sterically hindered platinum(II) complexes.
    Yu H, Gou S, Wang Z, Chen F, Fang L.
    Eur J Med Chem; 2016 May 23; 114():141-52. PubMed ID: 26974381
    [Abstract] [Full Text] [Related]

  • 7. Synthesis of trans-bis-(2-hydroxypyridine)dichloroplatinum(II) and its activity in human ovarian tumour models.
    Deqnah N, Yu JQ, Beale P, Fisher K, Huq F.
    Anticancer Res; 2012 Jan 23; 32(1):135-40. PubMed ID: 22213298
    [Abstract] [Full Text] [Related]

  • 8. Targeted iron nanoparticles with platinum-(IV) prodrugs and anti-EZH2 siRNA show great synergy in combating drug resistance in vitro and in vivo.
    Yu C, Ding B, Zhang X, Deng X, Deng K, Cheng Z, Xing B, Jin D, Ma P, Lin J.
    Biomaterials; 2018 Feb 23; 155():112-123. PubMed ID: 29175080
    [Abstract] [Full Text] [Related]

  • 9. Conjugation of platinum(IV) complexes with chlorambucil to overcome cisplatin resistance via a "joint action" mode toward DNA.
    Qin X, Fang L, Chen F, Gou S.
    Eur J Med Chem; 2017 Sep 08; 137():167-175. PubMed ID: 28586717
    [Abstract] [Full Text] [Related]

  • 10. Dinuclear platinum anticancer complexes with fluorescent N,N'-bis(aminoalkyl)-1,4-diaminoanthraquinones: cellular processing in two cisplatin-resistant cell lines reflects the differences in their resistance profiles.
    Kalayda GV, Jansen BA, Wielaard P, Tanke HJ, Reedijk J.
    J Biol Inorg Chem; 2005 May 08; 10(3):305-15. PubMed ID: 15824924
    [Abstract] [Full Text] [Related]

  • 11. New platinum(IV) complex with adamantylamine ligand as a promising anti-cancer drug: comparison of in vitro cytotoxic potential towards A2780/cisR cisplatin-resistant cell line within homologous series of platinum(IV) complexes.
    Turánek J, Kasná A, Záluská D, Neca J, Kvardová V, Knötigová P, Horváth V, SIndlerová L, Kozubík A, Sova P, Kroutil A, Zák F, Mistr A.
    Anticancer Drugs; 2004 Jun 08; 15(5):537-43. PubMed ID: 15166629
    [Abstract] [Full Text] [Related]

  • 12. Pt(IV) prodrugs containing microtubule inhibitors displayed potent antitumor activity and ability to overcome cisplatin resistance.
    Li L, Huang X, Huang R, Gou S, Wang Z, Wang H.
    Eur J Med Chem; 2018 Aug 05; 156():666-679. PubMed ID: 30031977
    [Abstract] [Full Text] [Related]

  • 13. Chemotherapeutic Potential of Chlorambucil-Platinum(IV) Prodrugs against Cisplatin-Resistant Colorectal Cancer Cells.
    Elias MG, Aputen AD, Fatima S, Mann TJ, Karan S, Mikhael M, de Souza P, Gordon CP, Scott KF, Aldrich-Wright JR.
    Int J Mol Sci; 2024 Jul 28; 25(15):. PubMed ID: 39125821
    [Abstract] [Full Text] [Related]

  • 14. Fatty acid-like Pt(IV) prodrugs overcome cisplatin resistance in ovarian cancer by harnessing CD36.
    Jayawardhana AMDS, Stilgenbauer M, Datta P, Qiu Z, Mckenzie S, Wang H, Bowers D, Kurokawa M, Zheng YR.
    Chem Commun (Camb); 2020 Sep 15; 56(73):10706-10709. PubMed ID: 32789350
    [Abstract] [Full Text] [Related]

  • 15. Platinum(iv) prodrugs with long lipid chains for drug delivery and overcoming cisplatin resistance.
    Chen Q, Yang Y, Lin X, Ma W, Chen G, Li W, Wang X, Yu Z.
    Chem Commun (Camb); 2018 May 22; 54(42):5369-5372. PubMed ID: 29744485
    [Abstract] [Full Text] [Related]

  • 16. Costunolide induces apoptosis in platinum-resistant human ovarian cancer cells by generating reactive oxygen species.
    Yang YI, Kim JH, Lee KT, Choi JH.
    Gynecol Oncol; 2011 Dec 22; 123(3):588-96. PubMed ID: 21945308
    [Abstract] [Full Text] [Related]

  • 17. Gene-specific repair of Pt/DNA lesions and induction of apoptosis by the oral platinum drug JM216 in three human ovarian carcinoma cell lines sensitive and resistant to cisplatin.
    O'Neill CF, Koberle B, Masters JR, Kelland LR.
    Br J Cancer; 1999 Dec 22; 81(8):1294-303. PubMed ID: 10604725
    [Abstract] [Full Text] [Related]

  • 18. Modulation of the cellular pharmacology of JM118, the major metabolite of satraplatin, by copper influx and efflux transporters.
    Samimi G, Howell SB.
    Cancer Chemother Pharmacol; 2006 Jun 22; 57(6):781-8. PubMed ID: 16170571
    [Abstract] [Full Text] [Related]

  • 19. A platinum prodrug conjugated with a photosensitizer with aggregation-induced emission (AIE) characteristics for drug activation monitoring and combinatorial photodynamic-chemotherapy against cisplatin resistant cancer cells.
    Yuan Y, Zhang CJ, Liu B.
    Chem Commun (Camb); 2015 May 21; 51(41):8626-9. PubMed ID: 25898264
    [Abstract] [Full Text] [Related]

  • 20. Transport of cisplatin and bis-acetato-ammine-dichlorocyclohexylamine Platinum(IV) (JM216) in human ovarian carcinoma cell lines: identification of a plasma membrane protein associated with cisplatin resistance.
    Sharp SY, Rogers PM, Kelland LR.
    Clin Cancer Res; 1995 Sep 21; 1(9):981-9. PubMed ID: 9816070
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.